{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:54:34Z","timestamp":1770749674817,"version":"3.50.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ministry of Higher Education, Science and Technology with the project \u201cPendanaan Riset Pembangunan Berkelanjutan (PRPB) Skema Kerja Sama Luar Negeri (KLN) Batch I","award":["No. 003\/E5\/PG.02.00\/PRPB BATCH 1\/2024"],"award-info":[{"award-number":["No. 003\/E5\/PG.02.00\/PRPB BATCH 1\/2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03135-z","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:20:01Z","timestamp":1764732001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CCA-1.1 Destabilizes MYC proteins to induce irreversible anti-proliferative effects in hepatocellular carcinoma"],"prefix":"10.1007","volume":"43","author":[{"given":"Rohmad Yudi","family":"Utomo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Novia Permata","family":"Hapsari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadzifa","family":"Nugraheni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beni","family":"Lestari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Hanifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni Putu","family":"Linda Laksmiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ummi Maryam","family":"Zulfin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthi","family":"Ikawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Suenaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Hippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edy","family":"Meiyanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riris Istighfari","family":"Jenie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"3135_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"key":"3135_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"key":"3135_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9.","journal-title":"Lancet"},{"key":"3135_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002.","journal-title":"N Engl J Med"},{"key":"3135_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1097277","author":"L Jiang","year":"2023","unstructured":"Jiang L, Li L, Liu Y, et al. Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1097277.","journal-title":"Front Pharmacol"},{"key":"3135_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.752725","volume":"11","author":"L Mou","year":"2021","unstructured":"Mou L, Tian X, Zhou B, et al. Improving outcomes of tyrosine kinase inhibitors in hepatocellular carcinoma: new data and ongoing trials. Front Oncol. 2021;11:752725. https:\/\/doi.org\/10.3389\/fonc.2021.752725.","journal-title":"Front Oncol"},{"key":"3135_CR7","doi-asserted-by":"publisher","first-page":"e1003996","DOI":"10.1371\/journal.pgen.1003996","volume":"10","author":"Y Suenaga","year":"2014","unstructured":"Suenaga Y, Islam SMR, Alagu J, et al. NCYM, a cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3\u03b2 resulting in the stabilization of MYCN in human neuroblastomas. PLoS Genet. 2014;10:e1003996. https:\/\/doi.org\/10.1371\/journal.pgen.1003996.","journal-title":"PLoS Genet"},{"key":"3135_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2257-y","volume":"11","author":"X-Y Qin","year":"2020","unstructured":"Qin X-Y, Su T, Yu W, Kojima S. Lipid desaturation-associated endoplasmic reticulum stress regulates MYCN gene expression in hepatocellular carcinoma cells. Cell Death Dis. 2020;11:1\u201313. https:\/\/doi.org\/10.1038\/s41419-020-2257-y.","journal-title":"Cell Death Dis"},{"key":"3135_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.618515","volume":"10","author":"X-Y Qin","year":"2021","unstructured":"Qin X-Y, Gailhouste L. Non-genomic control of dynamic MYCN gene expression in liver cancer. Front Oncol. 2021;10:618515. https:\/\/doi.org\/10.3389\/fonc.2020.618515.","journal-title":"Front Oncol"},{"key":"3135_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/genes8040123","volume":"8","author":"K Zheng","year":"2017","unstructured":"Zheng K, Cubero FJ, Nevzorova YA. c-MYC\u2014making liver sick: role of c-MYC in hepatic cell function, homeostasis and disease. Genes. 2017;8:123. https:\/\/doi.org\/10.3390\/genes8040123.","journal-title":"Genes"},{"key":"3135_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054746","volume":"24","author":"D Boi","year":"2023","unstructured":"Boi D, Rubini E, Breccia S, et al. When just one phosphate is one too many: the multifaceted interplay between Myc and kinases. Int J Mol Sci. 2023;24:4746. https:\/\/doi.org\/10.3390\/ijms24054746.","journal-title":"Int J Mol Sci"},{"key":"3135_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ncb1110","volume":"6","author":"E Yeh","year":"2004","unstructured":"Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308\u201318. https:\/\/doi.org\/10.1038\/ncb1110.","journal-title":"Nat Cell Biol"},{"key":"3135_CR13","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","volume":"14","author":"R Sears","year":"2000","unstructured":"Sears R, Nuckolls F, Haura E, et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501\u201314. https:\/\/doi.org\/10.1101\/gad.836800.","journal-title":"Genes Dev"},{"key":"3135_CR14","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood.V126.23.2450.2450","volume":"126","author":"FX Schaub","year":"2015","unstructured":"Schaub FX, Li W, Fallahi M, et al. Myc-directed suppression of autophagy provides therapeutic vulnerabilities targeting amino acid homeostasis. Blood. 2015;126:2450. https:\/\/doi.org\/10.1182\/blood.V126.23.2450.2450.","journal-title":"Blood"},{"key":"3135_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.34172\/apb.2022.063","volume":"12","author":"RY Utomo","year":"2021","unstructured":"Utomo RY, Wulandari F, Novitasari D, et al. Preparation and cytotoxic evaluation of PGV-1 derivative, CCA-1.1, as a new Curcumin analog with improved-physicochemical and pharmacological properties. Adv Pharm Bull. 2021;12:603\u201312. https:\/\/doi.org\/10.34172\/apb.2022.063.","journal-title":"Adv Pharm Bull"},{"key":"3135_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.34172\/apb.2024.058","volume":"14","author":"N Nugraheni","year":"2024","unstructured":"Nugraheni N, Zulfin UM, Lestari B, et al. PGV-1 causes disarrangement of spindle microtubule organization resulting in aberrant mitosis in HLF and HuH6 cells associated with altered MYCN status. Adv Pharm Bull. 2024;14:665\u201374. https:\/\/doi.org\/10.34172\/apb.2024.058.","journal-title":"Adv Pharm Bull"},{"key":"3135_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.22146\/ijp.10610","volume":"35","author":"M Moordiani","year":"2024","unstructured":"Moordiani M, Novitasari D, Susidarti RA, et al. Pentagamavunone-1 suppresses MYCN-positive HuH-7 cancer cell growth via mitotic arrest in vitro. Indones J Pharm. 2024;35:649\u201359. https:\/\/doi.org\/10.22146\/ijp.10610.","journal-title":"Indones J Pharm"},{"key":"3135_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.18585\/inabj.v13i3.1583","volume":"13","author":"F Wulandari","year":"2021","unstructured":"Wulandari F, Ikawati M, Kirihata M, et al. Curcumin analogs, PGV-1 and CCA-1.1 exhibit anti-migratory effects and suppress MMP9 expression on WiDr cells. Indones Biomed J. 2021;13:271\u201380. https:\/\/doi.org\/10.18585\/inabj.v13i3.1583.","journal-title":"Indones Biomed J"},{"key":"3135_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.18585\/inabj.v15i2.2147","volume":"15","author":"M Moordiani","year":"2023","unstructured":"Moordiani M, Novitasari D, Susidarti RA, et al. Curcumin analogs PGV-1 and CCA-1.1 induce cell cycle arrest in human hepatocellular carcinoma cells with overexpressed MYCN. Indones Biomed J. 2023;15:141\u20139. https:\/\/doi.org\/10.18585\/inabj.v15i2.2147.","journal-title":"Indones Biomed J"},{"key":"3135_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-51244-3","volume":"9","author":"B Lestari","year":"2019","unstructured":"Lestari B, Nakamae I, Yoneda-Kato N, et al. Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. Sci Rep. 2019;9:1\u201312. https:\/\/doi.org\/10.1038\/s41598-019-51244-3.","journal-title":"Sci Rep"},{"key":"3135_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12906-025-05004-8","volume":"25","author":"B Lestari","year":"2025","unstructured":"Lestari B, Utomo RY, Rahman FA, et al. Discovery of pyroptosis-inducing natural products in neuroblastomas: computational studies with experimental validation. BMC Complement Med Ther. 2025;25:279. https:\/\/doi.org\/10.1186\/s12906-025-05004-8.","journal-title":"BMC Complement Med Ther"},{"key":"3135_CR22","doi-asserted-by":"publisher","DOI":"10.1063\/5.0014475","volume":"153","author":"JC Phillips","year":"2020","unstructured":"Phillips JC, Hardy DJ, Maia JDC, et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. J Chem Phys. 2020;153:044130. https:\/\/doi.org\/10.1063\/5.0014475.","journal-title":"J Chem Phys"},{"key":"3135_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol\/ Graph. 1996;14:33\u20138. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5.","journal-title":"J Mol\/ Graph"},{"key":"3135_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149:22\u201335. https:\/\/doi.org\/10.1016\/j.cell.2012.03.003.","journal-title":"Cell"},{"key":"3135_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103756","volume":"75","author":"V Llombart","year":"2022","unstructured":"Llombart V, Mansour MR. Therapeutic targeting of \u201cundruggable\u201d MYC. eBioMedicine. 2022;75:103756. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103756.","journal-title":"eBioMedicine"},{"key":"3135_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nrc904","volume":"2","author":"S Pelengaris","year":"2002","unstructured":"Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002;2:764\u201376. https:\/\/doi.org\/10.1038\/nrc904.","journal-title":"Nat Rev Cancer"},{"key":"3135_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-020-01291-6","volume":"20","author":"SK Madden","year":"2021","unstructured":"Madden SK, de Araujo AD, Gerhardt M, et al. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer. 2021;20:3. https:\/\/doi.org\/10.1186\/s12943-020-01291-6.","journal-title":"Mol Cancer"},{"key":"3135_CR28","doi-asserted-by":"publisher","first-page":"13928","DOI":"10.1038\/s41598-022-18348-9","volume":"12","author":"A Hermawan","year":"2022","unstructured":"Hermawan A, Wulandari F, Hanif N, et al. Identification of potential targets of the Curcumin analog CCA-1.1 for glioblastoma treatment: integrated computational analysis and in vitro study. Sci Rep. 2022;12:13928. https:\/\/doi.org\/10.1038\/s41598-022-18348-9.","journal-title":"Sci Rep"},{"key":"3135_CR29","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.31557\/APJCP.2021.22.6.1827","volume":"22","author":"D Novitasari","year":"2021","unstructured":"Novitasari D, Jenie RI, Utomo RY, et al. CCA-1.1, a novel Curcumin Analog, exerts cytotoxic anti- migratory activity toward TNBC and HER2-Enriched breast cancer cells. Asian Pac J Cancer Prev. 2021;22:1827\u201336. https:\/\/doi.org\/10.31557\/APJCP.2021.22.6.1827.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3135_CR30","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.52711\/0974-360X.2021.00760","volume":"14","author":"D Novitasari","year":"2021","unstructured":"Novitasari D, Jenie RI, Wulandari F, et al. Curcumin-like structure (CCA-1.1) induces permanent mitotic arrest (Senescence) on Triple-negative breast cancer (TNBC) cells, 4T1. Res J Pharm Technol. 2021;14:4375\u201382. https:\/\/doi.org\/10.52711\/0974-360X.2021.00760.","journal-title":"Res J Pharm Technol"},{"key":"3135_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nm1263","volume":"11","author":"G Kroemer","year":"2005","unstructured":"Kroemer G, Martin S. Caspase-independent cell death. Nat Med. 2005;11:725\u201330. https:\/\/doi.org\/10.1038\/nm1263.","journal-title":"Nat Med"},{"key":"3135_CR32","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/ncb3031","volume":"16","author":"H Lanaya","year":"2014","unstructured":"Lanaya H, Natarajan A, Komposch K, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014;16:972\u201381. https:\/\/doi.org\/10.1038\/ncb3031.","journal-title":"Nat Cell Biol"},{"key":"3135_CR33","doi-asserted-by":"publisher","first-page":"14039","DOI":"10.1200\/jco.2006.24.18_suppl.14039","volume":"24","author":"S Morinaga","year":"2006","unstructured":"Morinaga S, Nakamura Y, Sugano N, et al. Expression of epidermal growth factor receptor (EGFR) associates with proliferation, apoptosis, and histologically aggressive features in hepatocellular carcinoma. J Clin Oncol. 2006;24:14039\u201314039. https:\/\/doi.org\/10.1200\/jco.2006.24.18_suppl.14039.","journal-title":"J Clin Oncol"},{"key":"3135_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-022-04796-8","volume":"13","author":"S Song","year":"2022","unstructured":"Song S, Yu Z, You Y, et al. EGFR\/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli. Cell Death Dis. 2022;13:351. https:\/\/doi.org\/10.1038\/s41419-022-04796-8.","journal-title":"Cell Death Dis"},{"key":"3135_CR35","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/modpathol.3800665","volume":"19","author":"R Kannangai","year":"2006","unstructured":"Kannangai R, Sahin F, Torbenson MS. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol. 2006;19:1456\u201361. https:\/\/doi.org\/10.1038\/modpathol.3800665.","journal-title":"Mod Pathol"},{"key":"3135_CR36","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bbamcr.2006.11.010","volume":"1773","author":"J-C Chambard","year":"2007","unstructured":"Chambard J-C, Lefloch R, Pouyss\u00e9gur J, Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta Mol Cell Res. 2007;1773:1299\u2013310. https:\/\/doi.org\/10.1016\/j.bbamcr.2006.11.010.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"3135_CR37","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.3390\/ijms24032848","volume":"24","author":"A Javed","year":"2023","unstructured":"Javed A, Yarmohammadi M, Korkmaz KS, Rubio-Tom\u00e1s T. The regulation of cyclins and cyclin-dependent kinases in the development of gastric cancer. Int J Mol Sci. 2023;24:2848. https:\/\/doi.org\/10.3390\/ijms24032848.","journal-title":"Int J Mol Sci"},{"key":"3135_CR38","doi-asserted-by":"publisher","first-page":"9327","DOI":"10.18632\/oncotarget.3313","volume":"6","author":"J Li","year":"2015","unstructured":"Li J, Hong MJ, Chow JPH, et al. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe. Oncotarget. 2015;6:9327\u201340. https:\/\/doi.org\/10.18632\/oncotarget.3313.","journal-title":"Oncotarget"},{"key":"3135_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118743","volume":"1867","author":"MR Emma","year":"2020","unstructured":"Emma MR, Augello G, Cusimano A, et al. GSK-3 in liver diseases: friend or foe? Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2020;1867:118743. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118743.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"3135_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.803443","volume":"11","author":"Y Suenaga","year":"2021","unstructured":"Suenaga Y, Einvik C, Takatori A, Zhu Y. Editorial: molecular mechanisms and treatment of MYCN-driven tumors. Front Oncol. 2021;11:803443. https:\/\/doi.org\/10.3389\/fonc.2021.803443.","journal-title":"Front Oncol"},{"key":"3135_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633579","volume":"11","author":"C Pan","year":"2021","unstructured":"Pan C, Zhu Y, Yu M, et al. Control analysis of protein-protein interaction network reveals potential regulatory targets for MYCN. Front Oncol. 2021;11:633579. https:\/\/doi.org\/10.3389\/fonc.2021.633579.","journal-title":"Front Oncol"},{"key":"3135_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/jjco\/hyaa097","volume":"50","author":"Y Suenaga","year":"2020","unstructured":"Suenaga Y, Nakatani K, Nakagawara A. De novo evolved gene product NCYM in the pathogenesis and clinical outcome of human neuroblastomas and other cancers. Jpn J Clin Oncol. 2020;50:839\u201346. https:\/\/doi.org\/10.1093\/jjco\/hyaa097.","journal-title":"Jpn J Clin Oncol"},{"key":"3135_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/ncb3072","volume":"17","author":"V Cianfanelli","year":"2015","unstructured":"Cianfanelli V, Fuoco C, Lorente M, et al. AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. Nat Cell Biol. 2015;17:20\u201330. https:\/\/doi.org\/10.1038\/ncb3072.","journal-title":"Nat Cell Biol"},{"key":"3135_CR44","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1093\/hmg\/ddt381","volume":"22","author":"PPC Toh","year":"2013","unstructured":"Toh PPC, Luo S, Menzies FM, et al. Myc inhibition impairs autophagosome formation. Hum Mol Genet. 2013;22:5237\u201348. https:\/\/doi.org\/10.1093\/hmg\/ddt381.","journal-title":"Hum Mol Genet"},{"key":"3135_CR45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406936121","volume":"121","author":"W-L Ye","year":"2024","unstructured":"Ye W-L, Huang L, Yang X-Q, et al. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer. Proc Natl Acad Sci USA. 2024;121:e2406936121. https:\/\/doi.org\/10.1073\/pnas.2406936121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3135_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2420011122","volume":"122","author":"R Pandher","year":"2025","unstructured":"Pandher R, Xue C, Gamble LD, et al. The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response. Proc Natl Acad Sci USA. 2025;122:e2420011122. https:\/\/doi.org\/10.1073\/pnas.2420011122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3135_CR47","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1021\/acs.jmedchem.4c02556","volume":"68","author":"OA Obisesan","year":"2025","unstructured":"Obisesan OA, Ofori S, Orobator ON, et al. Discovery of a pyrazolopyridinone-based MYC inhibitor that selectively engages intracellular c-MYC and disrupts MYC\u2013MAX heterodimerization. J Med Chem. 2025;68:6233\u201351. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02556.","journal-title":"J Med Chem"},{"key":"3135_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1601975","author":"J Yu","year":"2025","unstructured":"Yu J, Liu D, Yuan Y, et al. Rethinking MYC inhibition: a multi-dimensional approach to overcome cancer\u2019s master regulator. Front Cell Dev Biol. 2025. https:\/\/doi.org\/10.3389\/fcell.2025.1601975.","journal-title":"Front Cell Dev Biol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03135-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:51:10Z","timestamp":1769485870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03135-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3135"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03135-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the final version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}